- Home
- IXHL vs FGEN Comparison
IXHL vs FGEN Comparison
Compare IXHL & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- FGEN
- Stock Information
- Founded
- IXHL 2001
- FGEN 1993
- Country
- IXHL Australia
- FGEN United States
- Employees
- IXHL N/A
- FGEN N/A
- Industry
- IXHL
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- FGEN Health Care
- Exchange
- IXHL Nasdaq
- FGEN Nasdaq
- Market Cap
- IXHL 35.6M
- FGEN 38.4M
- IPO Year
- IXHL N/A
- FGEN 2014
- Fundamental
- Price
- IXHL $0.58
- FGEN $11.29
- Analyst Decision
- IXHL
- FGEN Strong Buy
- Analyst Count
- IXHL 0
- FGEN 2
- Target Price
- IXHL N/A
- FGEN $146.50
- AVG Volume (30 Days)
- IXHL 117.4M
- FGEN 73.5K
- Earning Date
- IXHL 09-29-2025
- FGEN 08-11-2025
- Dividend Yield
- IXHL N/A
- FGEN N/A
- EPS Growth
- IXHL N/A
- FGEN N/A
- EPS
- IXHL N/A
- FGEN N/A
- Revenue
- IXHL $98,000.00
- FGEN $7,346,000.00
- Revenue This Year
- IXHL $2,538.49
- FGEN N/A
- Revenue Next Year
- IXHL $249.95
- FGEN N/A
- P/E Ratio
- IXHL N/A
- FGEN N/A
- Revenue Growth
- IXHL N/A
- FGEN N/A
- 52 Week Low
- IXHL $0.08
- FGEN $4.50
- 52 Week High
- IXHL $3.12
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- IXHL 51.37
- FGEN 58.97
- Support Level
- IXHL $0.51
- FGEN $10.65
- Resistance Level
- IXHL $0.92
- FGEN $12.60
- Average True Range (ATR)
- IXHL 0.09
- FGEN 0.86
- MACD
- IXHL -0.00
- FGEN -0.02
- Stochastic Oscillator
- IXHL 37.18
- FGEN 47.60
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.